4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated
Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial
Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational
Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Study
Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75
Upcoming Celebration Event
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin a laoreet magna, nec interdum nibh. Aliquam at lacinia arcu. Fusce vulputate mauris quis eros efficitur vehicula. Sed eget volutpat ipsum. Duis eget dui facilisis, interdum sapien a, rhoncus dolor. Sed pulvinar risus vel metus blandit, non consequat risus rhoncus.